Dr. Ranganathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
950 Campbell Ave
Psychiatry Service/116a
West Haven, CT 06516Phone+1 203-932-5711
Education & Training
- SUNY Downstate Health Sciences UniversityResidency, Psychiatry, 2002 - 2005
- Calicut Medical CollegeClass of 1999
Certifications & Licensure
- CT State Medical License 2006 - 2025
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Start of enrollment: 2009 Feb 01
- Effects of Salvinorin A in Healthy Controls Start of enrollment: 2009 Feb 12
- The Effects of Cannabidiol and ∆-9-THC in Humans Start of enrollment: 2010 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsmTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.Lynnette A Averill, Christopher L Averill, Ralitza Gueorguieva, Samar Fouda, Mohamed Sherif
Journal of Affective Disorders. 2022-04-15 - 5 citationsSex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).Anahita Bassir Nia, Maria J Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D'Souza
Psychopharmacology. 2022-05-01 - 53 citationsExploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.Deepak Cyril D'Souza, Shariful A Syed, L Taylor Flynn, Hamideh Safi-Aghdam, Nicholas V Cozzi
Neuropsychopharmacology. 2022-09-01
Journal Articles
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMohini Ranganathan, John H Krystal, JAMA Network Open
Authored Content
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
Press Mentions
- Cannabidiol Drugs Clinical Trial Outcomes and Adverse EffectsFebruary 25th, 2020
- Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)December 29th, 2017
- Why Some People Can't Handle Their WeedMay 15th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: